EC votes for "Europe for Patients"

26 April 2009

The European Parliament has voted in favor of three major health policy initiatives: patients rights in cross-border health care; improving  patient safety; and a European Union strategy on rare diseases  (Marketletters passim). The latter aims to improve the recognition of  rare, or "orphan," diseases which affect up to 6% of the total EU  population, or 29 million to 36 million people, and pool expertise,  experience and research to maximize the effective use of resources to  the benefit of all patients with these conditions. It also calls for  wider international collaboration in this area.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight